TransMedics Group, Inc. (TMDX) witnessed a significant surge in its stock price, soaring 6.77% in the pre-market session on Friday. This impressive rally was fueled by the company's exceptional fourth-quarter 2024 financial results and a robust outlook for the year 2025.
The medical technology company reported better-than-expected earnings and revenue for the fourth quarter. Earnings per share came in at $0.19, surpassing analysts' estimates of $0.18. Revenue skyrocketed 49.83% year-over-year to $121.62 million, significantly exceeding the consensus estimate of $110.29 million.
TransMedics Group's strong performance was driven by robust demand for its products and services, as well as operational efficiency and improved profitability. The company reported a gross margin of 59% and achieved positive income from operations and net income, further bolstering investor confidence.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。